Daily Stock Analysis, FGEN, FibroGen Inc, priceseries

FibroGen Inc. Daily Stock Analysis
Stock Information
Open
57.21
Close
55.89
High
57.21
Low
55.61
Previous Close
57.45
Daily Price Gain
-1.56
YTD High
59.48
YTD High Date
Feb 13, 2019
YTD Low
42.50
YTD Low Date
Jan 3, 2019
YTD Price Change
10.07
YTD Gain
21.98%
52 Week High
68.55
52 Week High Date
Jul 9, 2018
52 Week Low
37.27
52 Week Low Date
Dec 10, 2018
52 Week Price Change
-0.31
52 Week Gain
-0.55%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 13. 2017
25.25
May 5. 2017
27.51
15 Trading Days
8.94%
Link
LONG
Jun 20. 2017
30.15
Jul 13. 2017
32.25
16 Trading Days
6.97%
Link
LONG
Aug 28. 2017
43.50
Sep 22. 2017
51.11
18 Trading Days
17.50%
Link
LONG
Dec 20. 2017
44.55
Jan 4. 2018
48.00
9 Trading Days
7.74%
Link
LONG
Jan 22. 2018
49.90
Feb 2. 2018
56.74
9 Trading Days
13.71%
Link
LONG
May 30. 2018
52.70
Jun 26. 2018
61.83
19 Trading Days
17.32%
Link
LONG
Jan 4. 2019
45.36
Feb 20. 2019
56.29
31 Trading Days
24.09%
Link
Company Information
Stock Symbol
FGEN
Exchange
NasdaqGS
Company URL
http://www.fibrogen.com
Company Phone
415-978-1200
CEO
Thomas Byron Neff
Headquarters
California
Business Address
409 ILLINOIS STREET, SAN FRANCISCO, CA 94158
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000921299
About

FibroGen, Inc. operates as a research-based biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat unmet medical needs. It focuses on fibrosis and hypoxia-induced factor biology to generate programs targeting therapeutic areas. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Description

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.